Tuesday, June 24, 2014

The Motley Fool: A Big Step Forward for Vertex Pharmaceuticals, Inc

There was no shortage of uncertainty and controversy around Vertex's (NASDAQ: VRTX  ) phase 3 trials for its cystic fibrosis (or CF) combo therapy. Bernstein analyst Geoffrey Porges was perhaps the most visible bear recently, asserting on June 16 that "the probability of failure in this trial is high". Now that Vertex has actually released the data, the bears are licking their wounds – the results of the TRAFFIC and TRANSPORT studies were not perfect, but a "B+" ought to be more than enough to get FDA approval, leading to upwards of $5 billion in incremental revenue.

Read more here:
A Big Step Forward for Vertex Pharmaceuticals, Inc

No comments: